News · Etoday·

[BioS] SillaJen Presents Interim Results of Phase 1 Solid Tumor Trial of TTK/PLK1 at ESMO

Predicted impact: Low

Interim early-stage trial data presented at a conference; preclinical-stage news is vague.

Comments

Sign in to comment

No comments yet. Start the conversation.

Comments are people's own views. Nothing here is financial advice.